RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Metastasi epatiche da cancro del colon-retto: fattori di rischio, prognosi e trattamento su basi molecolari
• 2 - Valutazione della risposta tumorale con parametri biologici, immunologici e di imaging funzionale
• 3 - Avanzamenti nella diagnosi molecolare e nel trattamento dei tumori neuroendocrini
• 4 - Genomica e proteomica dei gliomi cerebrali: un approccio bioinformatico
• 5 - Caratterizzazione biomolecolare del carcinoma della mammella per lo sviluppo di terapie primarie sistemiche innovative
• 6 - Fisiopatologia,clinica e terapia dei tumori corticosurrenalici
• 7 - IDENTIFICAZIONE DI FATTORI MOLECOLARI PER LA VALUTAZIONE DEL RISCHIO METASTATICO NEI CARCINOMI COLORETTALI
• 8 - RUOLO DELLA FARMACOGENETICA NELLA DEFINIZIONE DELL'ATTIVITA' E TOLLERABILITA' DELLA CHEMIOTERAPIA ANTINEOPLASTICA
• 9 - Implicazioni diagnostico-terapeutiche delle nuove conoscenze cliniche e molecolari del carcinoma midollare della tiroide.
• 10 - Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma colorettale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ONCOLOGIA MEDICA
  • ANATOMIA PATOLOGICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Emilia Romagna

Bibliografia

Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. JClin Oncol 1998; 16(8):2672-85
Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-6.
P. Collecchi, E. Baldini, PG. Riannessi, et al. Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumorproliferative activity, BCL-2 expression and relationship between tumor regression and biological markers. Europ J Cancer 34,1701-1704, 1998
Bucholz TA, Davis DW, McConkey, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response tochemotherapy. Cancer Journal 2003;9(1):33-41.
Mac Grogan G, Rudolph P, Mascarel Id, et al. DNA topoisomerasi II alpha expression and the response to primary chemotherapy inbreast cancer. Br J Cancer 2003; 89(4):666-71
van't Veer LJ, Dai H, van De Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-36.
van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med2002;347:1999-2009.
Cleator S, Powles T, Dexter T, et al. Microarray expression profiles for predicting response to neoadjuvant AC chemotherapy.Breast Cancer Res Treat 2003 (suppl 1), S75, 322a.
Bucholz TA, Stivers DN, Stec J, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.Cancer J 2002;8(6):461-8.
Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identifyroutine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.Clin Cancer Res. 2003;9(7):2406-15.
Chang J C, Wooten E C, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel inpatients with breast cancer. The Lancet 2003;362:362-69.
Chang J, Ormerod M, Powles TJ, et al Apoptosis and proliferation as predictors of chemotherapy response in patients with breastcarcinoma. Cancer 2000;89(11):2145-52.
Wang J, Bucholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologicresponse to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002;94(12):3107-14.
Spector NL, Xia W, Burris H 3rd, et al. Study of the Biological Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies. J Clin Oncol. 2005 Jan 31[Epub ahead of print]
Chu I, Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit bothcell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan1;65(1):18-25.
Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breastcancer. Lancet. 2005 Feb 19;365(9460):671-9.
Kristensen VN, Sorlie T, Geisler J et al. Gene expression profiling of breast cancer in relation to estrogen receptor status andestrogen-metabolizing enzymes: clinical implications. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):878s-83s.
Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-CellSupport Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk PrimaryBreast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Mar 14; [Epub ahead of print]
Burcombe RJ, Makris A, Richman PI et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvantanthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005 Jan 17;92(1):147-55.
van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol. 2005 Mar 10;23(8):1631-5.
von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005 Jan;16(1):56-63.
Nakamura Y, Oka M, Soda H et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor,reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res. 2005 Feb 15;65(4):1541-6.
Schneeweiss A, Kolay S, Aulmann S et al Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). Anticancer Drugs. 2004 Mar;15(3):235-8.
Freedman OC, Verma S, Clemons MJ. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer TreatRev. 2005 Feb;31(1):1-17. Epub 2004 Nov 18.
Molino A, Micciolo R, Turazza M et al. Ki67 immunostaining in 322 primary breast cancers: association with clinical and pathological variables and prognosis. Int J Cancer 74: 433-437, 1997.
Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poorprognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997.
Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992.
Thor AD, Berry DA, Budman DR et al. ErbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J NatlCancer Inst 90: 1346-1360, 1998.
Elledge RM, Green S, Howes L et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breastcancer: a Southwest Oncology Group study. J Clin Oncol 15: 1916-1922, 1997.
Bukholm IRK, Bukholm G, Nesland JM. Reduced expression of both bax and bcl-2 is independently associated with lymph nodemetastasis in human breast carcinomas. APMIS 110: 214-218, 2002.
Cardone MH, Roy N, Stenicke HR et al . Regulation of cell death protease caspase-9 by phosphorylation . Science 282: 1318-1321, 1998.
Kang SS, Kwon T, Kwon DY et al. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274: 13085-13090, 1999.
Clark AS, West K, Streicher S et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther 1: 707-717, 2002.
Dahia PLM. PTEN, a unique tumor suppressor gene. Endocrine-Related Cancer 7: 115-129, 2000.
Leslie NR, Downes CP. PTEN: the downside of P13-kinase signaling. Cell Signal 14: 285-295, 2002.
Paramio JM, Navarro M, Segrelles C et al. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 18: 7462-7468, 1999.
Srivastava R. K. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia, 3: 535-546, 2001
Walczak H., Miller R. E., Ariail K., Gliniak B., Griffith T. S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R. G., Rauch C. T., Schuh J. C., Lynch D. H. Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat. Med., 5: 157-163, 1999.
French L. E., Tschopp J. The TRAIL to selective tumor death. Nat. Med., 5: 146-147, 1999.
Sorlie,T., Perou,C.M., Tibshirani et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A 98, 10869-10874.
Sorlie,T., Tibshirani,R., Parker,J et al(2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A 100, 8418-8423.

Parole Chiave

CARCINOMA MAMMARIO OPERABILE; TERAPIA SISTEMICA PRIMARIA; TERAPIE A BERSAGLIO MOLECOLARE; BIOMARCATORI TISSUTALI; PROFILO DI ESRESSIONE GENICA; ANTIBODY ARRAYS; STUDI CLINICI CONTROLLATI